Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -29.15% is in line with its 5-year average of -31.54%, around the middle of its 5-year range (-45.62%–-22.05%).
13.85% above its 12-month average of -33.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.25%.
RETURN ON ASSETS (ROA)
-29.15%
RETURN ON ASSETS (ROA) AVG TTM
-33.84%
RETURN ON ASSETS (ROA) AVG 3Y
-33.85%
RETURN ON ASSETS (ROA) AVG 5Y
-31.54%
RETURN ON ASSETS (ROA) AVG 10Y
-18.11%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+13.85%
CURRENT VS 3Y AVG
+13.88%
CURRENT VS 5Y AVG
+7.58%
CURRENT VS 10Y AVG
-60.99%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.07%
median of 561 covered companies
CURRENT VS SECTOR MEDIAN
-3.85%
vs the sector median at left
AC Immune S.A.
Market Cap
$260.54M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$266.17M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$264.73M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$262.00M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$260.75M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
Market Cap
$261.90M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$258.73M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$274.05M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$276.26M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AC Immune S.A. (ACIU) | $260.54M | -29.15% | -33.84% | -33.85% | -31.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | -35.96% | -58.88% | -82.10% | -113.46% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | -37.07% | -27.27% | -64.53% | -52.03% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | -134.38% | -47.50% | -42.91% | -40.55% |
| Century Therapeutics, Inc. (IPSC)vs › | $260.75M | -38.25% | -20.05% | -26.23% | -29.50% |
| Anika Therapeutics, Inc. (ANIK)vs › | $261.90M | -2.06% | -16.77% | -17.09% | -12.28% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $258.73M | -34.24% | -52.06% | -53.17% | -44.53% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.05M | -128.66% | -214.31% | -145.75% | -133.94% |
| Aurora Cannabis Inc. (ACB)vs › | $276.26M | -18.18% | -10.00% | -29.10% | -54.94% |
| Fate Therapeutics, Inc. (FATE)vs › | $279.74M | -48.44% | -42.51% | -39.18% | -34.60% |
ROA
-29.1%
ROE
-124.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -45.62% |
| 2024-12-31 | -22.05% |
| 2023-12-31 | -29.67% |
| 2022-12-31 | -38.05% |
| 2021-12-31 | -27.92% |
| 2020-12-31 | -25.94% |
| 2019-12-31 | 15.19% |
| 2018-12-31 | -25.92% |
| 2017-12-31 | -20.01% |
| 2016-12-31 | -4.55% |
| 2015-12-31 | 25.36% |
| 2014-12-31 | 35.46% |
| 2013-12-31 | -88.17% |
